Contributions of multimodal imaging

Por Oyen, Wim JG
Publicado no Cancer Imaging (2014)

Consensus Procedures in Oncological Imaging: The Case of Prostate Cancer

Por Fanti, Stefano, Oyen, Wim, Lalumera, Elisabetta
Publicado no Cancers (Basel) (2019)

FIAU: From reporter gene imaging to imaging of bacterial proliferation

Por Boerman, Otto C, Laverman, Peter, Oyen, Wim JG
Publicado em 2012

Predictive and prognostic value of FDG-PET

Por de Geus-Oei, Lioe-Fee, Oyen, Wim J.G.
Publicado em 2008

Nuclear medicine imaging and therapy of neuroendocrine tumours

Por Gotthardt, Martin, Dijkgraaf, Ingrid, Boerman, Otto C, Oyen, Wim J G
Publicado em 2006

Gastroparesis in patients with inactive Crohn's disease: a case series

Por Kristinsson, Jón O, Hopman, Wim PM, Oyen, Wim JG, Drenth, Joost PH
Publicado em 2007

Improved labelling of DTPA- and DOTA-conjugated peptides and antibodies with (111)In in HEPES and MES buffer

Por Brom, Maarten, Joosten, Lieke, Oyen, Wim JG, Gotthardt, Martin, Boerman, Otto C
Publicado em 2012

Radiolabelled peptides for oncological diagnosis

Por Laverman, Peter, Sosabowski, Jane K., Boerman, Otto C., Oyen, Wim J. G.
Publicado em 2012

Peritoneal Carcinomatosis of Colorectal Origin: Incidence and Current Treatment Strategies

Por Koppe, Manuel J., Boerman, Otto C., Oyen, Wim J. G., Bleichrodt, Robert P.
Publicado em 2006

Peritoneal Carcinomatosis of Colorectal Origin: Standard of Care

Por Koppe, Manuel J., Boerman, Otto C., Oyen, Wim J. G., Bleichrodt, Robert P.
Publicado em 2006

(68)Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET

Por Brom, Maarten, Oyen, Wim J. G., Joosten, Lieke, Gotthardt, Martin, Boerman, Otto C.
Publicado em 2010

Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas

Por Brom, Maarten, Joosten, Lieke, Oyen, Wim J.G., Gotthardt, Martin, Boerman, Otto C.
Publicado no Contrast Media Mol Imaging (2012)

FDG-PET/CT in a Patient with Poor-Risk Non-Seminoma Testis with Mature Teratoma and Secondary Gliosarcoma: Multimodality Imaging for Guiding Multimodality Treatment

Por Quak, Elske, Kovacs, Iringo, Oyen, Wim J. G., van der Graaf, Winette T. A.
Publicado no Nucl Med Mol Imaging (2015)

Methodological considerations in quantification of oncological FDG PET studies

Por Vriens, Dennis, Visser, Eric P., de Geus-Oei, Lioe-Fee, Oyen, Wim J. G.
Publicado em 2009

Multi-modality nuclear medicine imaging: artefacts, pitfalls and recommendations

Por van Dalen, Jorn A., Vogel, Wouter V., Corstens, Frans H.M., Oyen, Wim J.G.
Publicado em 2007

Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study

Por Schinagl, Dominic A. X., Span, Paul N., Oyen, Wim J., Kaanders, Johannes H. A. M.
Publicado em 2011

Immunotherapy response evaluation with (18)F-FDG-PET in patients with advanced stage renal cell carcinoma

Por Gilles, Rozemarie, de Geus-Oei, Lioe-Fee, Mulders, Peter F. A., Oyen, Wim J. G.
Publicado em 2011

EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems

Por Kaalep, Andres, Sera, Terez, Oyen, Wim, Krause, Bernd J., Chiti, Arturo, Liu, Yan, Boellaard, Ronald
Publicado no Eur J Nucl Med Mol Imaging (2017)

Radiolabeled antibodies in renal cell carcinoma

Por Stillebroer, Alexander B., Oosterwijk, Egbert, Oyen, Wim J.G., Mulders, Peter F.A., Boerman, Otto C.
Publicado em 2007

Antibody therapy in renal cell carcinoma

Por Oosterwijk, Egbert, Boerman, Otto C., Oyen, Wim J. C., Old, Lloyd J., Mulders, Peter F. A.
Publicado em 2008